METAP2 - Wikipedia
Methionine aminopeptidase 2, a member of the dimetallohydrolase family, is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from …
METAP2 Gene - GeneCards | MAP2 Protein | MAP2 Antibody
2024年12月25日 · METAP2 (Methionyl Aminopeptidase 2) is a Protein Coding gene. Diseases associated with METAP2 include Microsporidiosis and Liver Rhabdomyosarcoma . Among its …
甲硫氨酰氨肽酶 2（METAP2）基因 | MCE - MCE-生物活性 ...
编码的蛋白质通过保护真核起始因子 2 的 α 亚基免受抑制性磷酸化以及通过从新生蛋白质中去除氨基末端甲硫氨酸残基来发挥作用。 这种基因表达的增加与各种形式的癌症有关，抗癌药物夫 …
Targeting methionine aminopeptidase 2 in cancer, obesity, and ...
2021年10月1日 · For over three decades, methionine aminopeptidase 2 (MetAP2) has been a tentative drug target for the treatment of cancer, obesity, and autoimmune diseases. Currently, …
MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes …
2024年12月10日 · This review provides a comprehensive analysis of MetAP2, including its structural characteristics, catalytic mechanism, and functional roles in the pathophysiology of …
METAP2 methionyl aminopeptidase 2 [ (human)] - National …
2025年2月9日 · Results show that methionine aminopeptidase-2 (MetAP2) regulates angiogenesis in glioblastoma and identify MetAP2-specific substrates that may serve as …
High Expression of Methionine Aminopeptidase Type 2 in
2002年7月1日 · Methionine aminopeptidase type 2 (MetAP2) is a bifunctional protein that plays critical roles in the regulation of protein synthesis and post-translational processing by...
METAP2 methionyl aminopeptidase 2 [ Homo sapiens (human) ]
2024年11月27日 · Results show that methionine aminopeptidase-2 (MetAP2) regulates angiogenesis in glioblastoma and identify MetAP2-specific substrates that may serve as …
Metap2 - methionine aminopeptidase 2 基因 | MCE - MCE-生物活 …
Predicted to be involved in N-terminal protein amino acid modification; peptidyl-methionine modification; and protein processing. Predicted to act upstream of or within proteolysis. …
METAP2 - 药物、适应症、专利 - 智慧芽新药情报库
利用先前报道的metap2和parp1的小分子配体，研究人员开发了tram，结合这两种蛋白中的一种和fkbp12f36v。 然后，他们利用基因编辑技术构建了表达靶蛋白-FKBP12F36V融合体的细胞， …